Maverick Capital’s Filana Therapeutics FLNA Stock Holding History

Maverick Capital’s Portfolio FLNA Stock Details FLNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,637	Closed	-$140K	–	777
2021 Q2	$140K	Buy	+1,637	New	+$87.7K	﹤0.01%	530

Other funds holding FLNA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Maverick Capital's FLNA Position: Q3 2021 in Review

Maverick Capital sold out of Filana Therapeutics (FLNA) in Q3 2021, closing a stake of 1,637 shares — an estimated $140K sold.

Maverick Capital first reported a position in FLNA in Q2 2021 and held it in 1 quarter. The position peaked at $140K in Q2 2021. 180 funds tracked by Wall St. Rank hold FLNA as of Q3 2021.

Maverick Capital reported no remaining Filana Therapeutics position as of Q3 2021 after selling out during the quarter.
Maverick Capital sold 1,637 Filana Therapeutics shares in Q3 2021, an estimated $140K.
Maverick Capital first reported a position in Filana Therapeutics in Q2 2021 and held it in 1 quarter.
Maverick Capital's Filana Therapeutics position peaked at $140K in Q2 2021.
180 funds tracked by Wall St. Rank held Filana Therapeutics as of Q3 2021.

Based on Maverick Capital's 13F filing for Q3 2021, filed 15 Nov 2021.